EXO Biologics, a clinical-stage biotech company based in Liège, Belgium, has secured €16 million in Series A funding to advance its pioneering work with exosomes for therapeutic use. The funding includes €9 million from investors such as Noshaq, Founders, and Belgian Family Offices, with an additional €7 million in subsidies from the Public Service of Wallonia (SPW), including a significant portion through the Technological Innovation Partnership for Advanced Therapy Medicinal Products (ATMP-PIT) initiative.
The funding will enable EXO Biologics to accelerate its clinical trials, particularly the EVENEW trial authorized by the European Medicines Agency, which investigates the use of MSC-based exosomes in preventing Bronchopulmonary Dysplasia (BPD) in preterm newborns. EXOB-001, the company’s lead candidate, highlights this initiative, demonstrating the potential of exosomes to modulate the immune system and promote tissue repair.
Advertisement
Advancing Manufacturing and Global Outreach
EXO Biologics plans to use the funds to expand its manufacturing capabilities, including upgrading its unique production platform, ExoPulse. The company aims to enhance the platform and expand partnerships to facilitate GMP clinical-grade exosome production, expediting access to clinical trials.
The investment will also support EXO Biologics in its mission to bring exosome-based therapies to a global market, helping to address a range of diseases with unmet medical needs. The focus will be on respiratory diseases, inflammatory bowel diseases, neurology, and oncology.
Building on a Solid Foundation
EXO Biologics is supported by a wealth of experience from its leadership, including CEO Hugues Wallemacq. The company leverages this expertise to develop treatments that offer a safer alternative to conventional methods, using exosomes derived from human umbilical cord cells.
The strategic acquisition of funding and the technological advancement of their platforms position EXO Biologics to make significant contributions to the biopharmaceutical field, particularly in the development of therapies that reduce the environmental impact of disease treatment and enhance patient care globally.
